BMYClinical Trials•businesswire•June 12, 2025 at 10:59 AM

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Sentiment:Neutral (50)

Summary

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 12, 2025 by businesswire